Radiotherapy combined with Temozolomide (TMZ) improves outcomes in patients with malignant glioblastoma; however, O6-methylguanine-DNA methyltransferase (MGMT)-mediated DNA restore causes TMZ resistance. This evidence concerns the gene MGMT and glioblastoma.